Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 19/20 | 0.54 |
| ▸ | HTR1A | P08908 | 17/20 | 0.54 |
| ▸ | HTR2A | P28223 | 16/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697490 | 0.92 | DRD2 (0.54) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL22844470 | 0.92 | HTR1A (0.57) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL7842484 | 0.92 | DRD2 (0.54) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL18388386 | 0.91 | DRD2 (0.59) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL20260449 | 0.90 | DRD2 (0.52) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL20381907 | 0.90 | DRD2 (0.52) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL20260350 | 0.90 | DRD2 (0.56) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL18388440 | 0.89 | DRD2 (0.56) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL12930088 | 0.89 | HTR1A (0.58) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL19018781 | 0.88 | HTR1A (0.57) | DRD2HTR1AHTR2ASLC6A4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.